The only FDA-approved treatments for dry AMD as of 2023 are two injectable drugs, which are limited by concerns over complications from intravitreal injections and modest efficacy in restoring vision.
Lisa Jarvis is a Bloomberg Opinion columnist covering biotech, health care and the pharmaceutical industry. Previously, she was executive editor of Chemical & Engineering News. Anyone who has ...